EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE

Roger A Goldberg, Florie A Mar, Karl Csaky, Manuel Amador, Arshad M Khanani, Kara Gibson, Anton M Kolomeyer, Dawn A Sim, Toshinori Murata, Tracey Wang, Patricia Udaondo, Audrey Souverain und 4 weitere

Ophthalmology Retina · 2025-06 · 9 (6) · 515-526

DOI: 10.1016/j.oret.2024.11.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2025-06. Verfasst von Roger A Goldberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Bay Area Retina Associates, Walnut Creek, California. Electronic address: rgoldberg.eyemd@gmail.com. Hauptthemen laut MEDLINE: Capillary Permeability, Diabetic Retinopathy, Macula Lutea, Macular Edema. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate if dual angiopoietin-2 (Ang-2)/VEGF-A inhibition with faricimab resulted in greater macular leakage resolution versus aflibercept in patients with diabetic macular edema (DME). DESIGN: Post hoc analysis of macular leakage assessments prespecified in the YOSEMITE/RHINE (NCT03622580/NCT03622593) phase III trials. PARTICIPANTS: Adults with visual acuity loss due to center-involving DME. METHODS: Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks (Q8W), faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen, or aflibercept 2.0 mg Q8W. This analysis included the first 16 weeks (head-to-head dosing period) when all patients received assigned study drug every 4 weeks (Q4W); patients were assessed 4 weeks after receiving 4 doses of assigned study drug Q4W. MAIN OUTCOME MEASURES: Macular leakage area on fluorescein angiography assessed by a reading center; proportion of patients with resolution of macular leakage (defined as macular leakage area 0-1 mm2) and high macular leakage (defined as macular leakage area ≥10 mm2) at baseline and week 16; and the proportion of faricimab T&E patients receiving Q16W dosing at week 52 among those with resolution of and high macular leakage at week 16. RESULTS: Among patients with macular leakage data available at baseline, there were 1216 patients in the pooled faricimab (Q8W + T&E) arms and 593 patients in the aflibercept arm. Baseline median macular leakage area was similar between the faricimab (24.6 mm2) and aflibercept arms (25.6 mm2). At week 16, median macular leakage area was 3.6 mm2 with faricimab versus 7.6 mm2 with aflibercept (nominal P < 0.0001). More faricimab-treated patients (28%) achieved resolution of macular leakage versus aflibercept at week 16 (15%; nominal P < 0.0001). In the faricimab T&E arm, 63% of patients with resolution of macular leakage and 45% of patients with high macular leakage at week 16 achieved Q16W dosing at week 52 (nominal P < 0.01). CONCLUSIONS: Faricimab demonstrated greater macular leakage resolution versus aflibercept during head-to-head dosing. These findings suggest that dual Ang-2/VEGF-A inhibition promotes vascular stability beyond VEGF inhibition alone, supporting faricimab's potential to offer greater disease control and extend durability for patients with DME. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Capillary PermeabilityDiabetic RetinopathyMacula LuteaMacular EdemaReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityAgedFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsDose-Response Relationship, DrugDouble-Blind MethodFluorescein AngiographyFollow-Up StudiesFundus OculiIntravitreal InjectionsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AAntibodies, Bispecific

Stichwörter der Autor:innen

Angiopoietin-2Diabetic macular edemaFaricimabMacular leakageVascular endothelial growth factor-A

Substanzen

afliberceptAngiogenesis InhibitorsfaricimabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAntibodies, Bispecific

Autor:innen und Institutionen

  • Bay Area Retina Associates, Walnut Creek, California. Electronic address: rgoldberg.eyemd@gmail.com.
  • Genentech, Inc., South San Francisco, California.
  • Retina Foundation of the Southwest, Texas.
  • Sierra Eye Associates and University of Nevada, Reno School of Medicine, Reno, Nevada.
  • Roche Products Ltd., Welwyn Garden City, United Kingdom.
  • NJ Retina, New Brunswick, New Jersey.

Förderung

  • Roche
  • F. Hoffmann-La Roche

Zitieren

APA

Goldberg, R. A., Mar, F. A., Csaky, K., Amador, M., Khanani, A. M., Gibson, K., Kolomeyer, A. M., Sim, D. A., Murata, T., Wang, T., Udaondo, P., Souverain, A., Shildkrot, Y. E., Vujosevic, S., Nudleman, E., & Sivaprasad, S. (2025). Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Ophthalmology Retina, 9(6), 515-526. https://doi.org/10.1016/j.oret.2024.11.015

Vancouver

Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K, et al. Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Ophthalmology Retina. 2025;9(6):515-526. doi:10.1016/j.oret.2024.11.015

BibTeX
@article{Goldberg2025,
  author = {Goldberg, Roger A and Mar, Florie A and Csaky, Karl and Amador, Manuel and Khanani, Arshad M and Gibson, Kara and Kolomeyer, Anton M and Sim, Dawn A and Murata, Toshinori and Wang, Tracey and Udaondo, Patricia and Souverain, Audrey and Shildkrot, Yevgeniy Eugene and Vujosevic, Stela and Nudleman, Eric and Sivaprasad, Sobha},
  title = {Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE},
  journal = {Ophthalmology Retina},
  year = {2025},
  volume = {9},
  number = {6},
  pages = {515--526},
  doi = {10.1016/j.oret.2024.11.015}
}
Kostenlos starten →